Everything below concerns incretin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-13. Numbers and descriptions here follow the published literature rather than marketing material.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
=== Charles Hanani === Charles Hanani (Adam Levy) is Yasmin's father, and the wealthy CEO of the Hanani Publishing company. Charles is a serial philanderer, long divorced from Yasmin's mother Azar. He has a strained relationship with Yasmin, whom he treats like a child, and who carries trauma from growing up around her father's sexually inappropriate behavior. Charles reenters Yasmin’s life in series 2 when he arrives in London on business. Hoping to transition into Pierpoint’s private wealth management division, Yasmin brings him on as a client, only to learn that much of his fortune has been drained by nondisclosure settlements with women he had affairs with—including her former nanny, leading Yasmin to realize he likely groomed her. When confronted, Charles attacks Yasmin for condemning him while benefiting from his wealth and cuts her off financially. In series 3, Yasmin joins Charles on his yacht in Mallorca and catches him performing oral sex on a pregnant employee. Amid revelations that he is being sued by his own company for historic embezzlement, the two engage in a vicious confrontation in which Yasmin accuses him of sexualizing her throughout her life. A drunken Charles jumps overboard after Yasmin wishes him dead, and she makes no attempt to save him; Harper helps cover up her involvement. After Charles’ body is recovered, Hanani Publishing scapegoats Yasmin to deflect from its own complicity in silencing his victims, prompting her to sue the company.
Coagulation, the formation of a blood clot or thrombus, occurs when the proteins of the coagulation cascade are activated, either by contact with a damaged blood vessel wall and exposure to collagen in the tissue space (intrinsic pathway) or by activation of factor VII by tissue activating factors (extrinsic pathway). Both pathways lead to the generation of thrombin, an enzyme that turns the soluble blood protein fibrinogen into fibrin, which aggregates into protofibrils. Another thrombin-generated enzyme, factor XIII, then crosslinks the fibrin protofibrils at the D fragment site, leading to the formation of an insoluble gel that serves as a scaffold for blood clot formation. The circulating enzyme plasmin, the main enzyme of fibrinolysis, cleaves the fibrin gel in a number of places. The resultant fragments, "high molecular weight polymers", are digested several times more by plasmin to lead to intermediate and then to small polymers (fibrin degradation products or FDPs). The cross-link between two D fragments remains intact, however, and these are exposed on the surface when the fibrin fragments are sufficiently digested. The structure of D-dimer is either a 180 kDa or 195 kDa molecule of two D domains, or a 340 kDa molecule of two D domains and one E domain. The half-life of D-dimer in blood is approximately 6 to 8 hours. D-dimers are not normally present in human blood plasma, except when the coagulation system has been activated, for instance, because of the presence of thrombosis or disseminated intravascular coagulation.
One prominent case was the classification of ascolichen families by the structure of the ascus apex (the tip of the spore sac). Josef Hafellner (1984) reorganized many ascolichen families by ascus-apex staining (amyloid ring present vs. absent), treating that feature as primary. Later DNA work found several of those families to be polyphyletic: the ascus type had arisen independently in unrelated lineages. The results echoed Nylander's century-old warning against single-trait taxonomy. Leif Tibell (1998) urged that robust taxa rest on multiple, independent characters. Pier Luigi Nimis (1998) warned that elevating every apparent clade to genus rank risks "explosive inflation" and listed five tests—monophyly, formal analysis, ≥ 1 diagnostic trait, broad sampling, and demonstrable informational gain—before renaming species. Where those tests are not met, Nimis advised using subgeneric rank so that binomials remain stable. Tibell further separated goals: classification should provide a stable, useful scheme, whereas phylogeny seeks the full branching pattern. He argued that constant renaming for every new tree can undermine nomenclatural stability; revisions should await strong, multi-line evidence. These philosophical perspectives influenced how lichenologists handled emerging molecular results a few years later. By the late 1990s lichenologists, trained in data matrices and synapomorphy logic, were ready to fold DNA data into taxonomy.
List of nuclides shows all radionuclides with half-life > 1 hour Hyperaccumulators table – 3 (includes organisms noted for accumulating radionuclides) Radioactivity in biology Radiometric dating Radionuclide cisternogram Uses of radioactivity in oil and gas wells
== Treatment == Surgery, if feasible, is the only curative therapy. If the tumor has metastasized (most commonly, to the liver) and is considered incurable, there are some promising treatment modalities, such as the radiopharmaceuticals Lutetium (177Lu) DOTA-octreotate) and 131I-mIBG (meta iodo benzyl guanidine) for arresting the growth of the tumors and prolonging survival in patients with liver metastases, though these are currently experimental. Chemotherapy is of little benefit and is generally not indicated. Octreotide or lanreotide (somatostatin analogues) may decrease the secretory activity of the carcinoid, and may also have an anti-proliferative effect. Interferon treatment is also effective, and usually combined with somatostatin analogues. As the metastatic potential of a coincidental carcinoid is probably low, the current recommendation is for follow up in 3 months with CT or MRI, labs for tumor markers such as serotonin, and a history and physical, with annual physicals thereafter.
Sources: en.wikipedia.org
The Mystery of the Yellow Room (1913) The Mystery of the Yellow Room (1919) The Mystery of the Yellow Room (1930) El misterio del cuarto amarillo (1947) at IMDb The Mystery of the Yellow Room (1949) Mystère de la chambre jaune, Le (1965) at IMDb The Mystery of the Yellow Room (2003) An episode of Jonathan Creek features a stage adaptation of the novel and centres around a similar event happening to one of its actors. Radio:
Many soluble salts of acid dyes synthesized for textile-related purposes were transformed into insoluble salts or lake pigments by reaction with water-soluble salts of calcium, barium or lead, whereas basic dyes were treated with tannins or antimony potassium tartrate to yield pigments.
In it Adorno not only deviated from the theoretical program Horkheimer had laid out a year earlier but also challenged philosophy's very capacity for comprehending reality as such: "For the mind," Adorno announced, "is indeed not capable of producing or grasping the totality of the real, but it may be possible to penetrate the detail, to explode in miniature the mass of merely existing reality." In line with Benjamin's The Origin of German Tragic Drama and preliminary sketches of the Arcades Project, Adorno likened philosophical interpretation to experiments that should be conducted "until they arrive at figurations in which the answers are legible, while the questions themselves vanish." Having lost its position as the Queen of the Sciences, philosophy must now radically transform its approach to objects so that it might "construct keys before which reality springs open." Following Horkheimer's taking up the directorship of the Institute, a new journal, Zeitschrift für Sozialforschung, was produced to publish the research of Institute members both before and after its relocation to the United States. Though Adorno was not an Institute member, the journal published many of his essays, including "The Social Situation of Music" (1932), "On Jazz" (1936), "On the Fetish-Character in Music and the Regression of Listening" (1938), and "Fragments on Wagner" (1938).
Glutathione S-transferases (GSTs), previously known as ligandins, are a family of eukaryotic and prokaryotic phase II metabolic isozymes best known for their ability to catalyze the conjugation of the reduced form of glutathione (GSH) to xenobiotic substrates for the purpose of detoxification. The GST family consists of three superfamilies: the cytosolic, mitochondrial, and microsomal—also known as MAPEG—proteins. Members of the GST superfamily are extremely diverse in amino acid sequence, and a large fraction of the sequences deposited in public databases are of unknown function. The Enzyme Function Initiative (EFI) is using GSTs as a model superfamily to identify new GST functions. GSTs can constitute up to 10% of cytosolic protein in some mammalian organs. GSTs catalyse the conjugation of GSH—via a sulfhydryl group—to electrophilic centers on a wide variety of substrates in order to make the compounds more water-soluble. This activity detoxifies endogenous compounds such as peroxidised lipids and enables the breakdown of xenobiotics. GSTs may also bind toxins and function as transport proteins, which gave rise to the early term for GSTs, ligandin.
=== Post-finasteride syndrome === Reports of long-term, post-discontinuation adverse effects in some fraction of former finasteride users have led to a proposed post-finasteride syndrome (PFS), although some within the medical community question whether there is enough evidence to support a causal relationship between finasteride usage and persistent symptoms. Individuals claiming to experience PFS report sexual, neurological, hormonal, and psychological side effects that persist for an extended period after stopping the drug. Reported symptoms include penile atrophy and tissue changes, decreased ejaculate volume and quality, reduced libido, erectile dysfunction, loss of penile sensitivity, decreased orgasm sensation, dry skin, metabolic changes, muscle and strength loss, gynecomastia, depression, anxiety, panic attacks, insomnia, anhedonia, concentration problems, memory impairment and suicidal ideation. A meta-analysis found a significant association between finasteride use and post-discontinuation depression, suicidal ideation, and sexual dysfunction, but the quality of evidence was limited. The status of PFS as a legitimate and distinct medical pathology remains a subject of debate. A 2019 editorial in The BMJ called post-finasteride syndrome "ill defined and controversial".
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.